<DOC>
	<DOCNO>NCT00997672</DOCNO>
	<brief_summary>The purpose study determine safety tolerability treatment lithium Multiple System Atrophy . Moreover , clinical symptom , neuronal loss , quality life depressive symptom , consider investigate effect lithium therapy .</brief_summary>
	<brief_title>Lithium Multiple System Atrophy</brief_title>
	<detailed_description>Patients progressively enrol study undergo screen visit test inclusion/exclusion criterion . Patients randomize receive either Lithium carbonate placebo . Patients visit study center 2 , 4 , 8 , 12 , 24 , 36 48 week , endpoint laboratory assessment .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Clinical diagnosis probable MSA ( Gilman , et al . 2008 ) Age â‰¥18 , &lt; 80 Heart failure Liver disease Kidney failure Thyroid disease Sick sinus syndrome and/or significant ECG alteration Hyposodemia Treatment diuretic Treatment haloperidol and/or antipsychotic Treatment NSAIDs corticosteroid Treatment ACE inhibitor Treatment aminophylline Treatment mannitol Pregnancy and/or breastfeed Acute disease might interfere trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>MSA</keyword>
	<keyword>Lithium</keyword>
	<keyword>Lithium carbonate</keyword>
	<keyword>MSA-P</keyword>
	<keyword>MSA-C</keyword>
</DOC>